Ignite Creation Date:
2024-05-05 @ 11:49 PM
Last Modification Date:
2024-10-26 @ 10:39 AM
Study NCT ID:
NCT01420627
Status:
COMPLETED
Last Update Posted:
2020-04-16
First Post:
2011-08-18
Brief Title:
EZN-2279 in Patients With ADA-SCID
Sponsor:
Leadiant Biosciences Inc
Organization:
Leadiant Biosciences Inc
Study Overview
Official Title:
A Study of EZN-2279 Polyethylene Glycol Recombinant Adenosine Deaminase PEG-rADA Administered as a Weekly Intramuscular Injection in Patients With Adenosine Deaminase ADA-Deficient Combined Immunodeficiency
Status:
COMPLETED
Status Verified Date:
2020-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to evaluate the safety efficacy and pharmacokinetics of EZN-2279 in patients with ADA-deficient combined immunodeficiency currently being treated with Adagen
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None